Business Context and Reporting Period
This Form 8-K filing by Biorestorative Therapies, Inc. (Delaware) was dated February 16, 2016, with a signature date of March 24, 2016. The report details a series of unregistered equity and warrant issuances occurring between January 27, 2016, and March 18, 2016. The Company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 for these transactions, asserting that investors were accredited and no general solicitation was used.
Key Financial Metrics and Capital Activities
The filing outlines specific capital raising and debt settlement activities rather than standard operating financial metrics like revenue or net income.
- Director Investment: Sold 250,000 shares to Director John M. Desmarais at $4.00/share ($1,000,000 total).
- Private Placements: Issued 129,593 shares at $4.00/share between Jan 27 and Feb 29, 2016.
- Warrant Exercises: Issued 18,869 shares from Feb 11-16, 2016, at $3.50/share.
- Debt Settlement: Issued 96,410 shares between March 4-8, 2016, to settle $218,165 of indebtedness.
- Service Compensation: Issued 17,500 shares valued at $39,375 for services rendered.
- Loan Financing: Received a $250,000 loan on Feb 18, 2016, accompanied by a warrant valued at $35,400.
The filing text does not provide clear values for total revenue, operating profit, cash flow, or overall debt levels outside of the specific transactions listed above.
Material Changes and Transactions
The primary material change reported is the significant dilution of equity through multiple issuance events. Notable transactions include:
- Warrant Issuances:
- To Director Desmarais: Three warrants covering 1,094,444 shares total (exercise prices ranging from $4.50 to $5.00).
- To Private Subscribers: Warrants for 129,493 shares at $5.00/share.
- To Lender: Warrant for 20,000 shares at $4.00/share.
- Debt Reduction: The Company reduced outstanding indebtedness by $218,165 through a debt-for-equity swap.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of unregistered securities. The Company noted that investors had access to historical financial reports (10-K and 10-Qs) and that management was available to answer questions. The reliance on exemptions from registration indicates a continued need for private capital markets rather than public offerings.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess dilution impact.
- Confirm the status of the $250,000 loan received on February 18, 2016, and its repayment terms.
- Review the valuation methodology for the warrants issued, particularly the $35,400 valuation for the loan warrant.
- Check subsequent filings for the exercise status of the 1,243,937 warrants issued during this period.
- Confirm the Company's cash position following the $1,000,000 director investment and $250,000 loan.